Akari Therapeutics Plc (AKTX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $9.20
- As of
Kresmion compiles this page from AKTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Akari Therapeutics Plc (AKTX): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-01.
See the full AKTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AKTX on one page. Preview it with sample data, then open it live with a free account.
Preview the AKTX dossierActive events for AKTX
- mediumEarnings below estimates
Q2-2026: Missed consensus by 105.3%, EPS $-2.68 vs $-1.3056 estimate
- medium13F: new position
CITADEL ADVISORS LLC new position in AKTX
- mediumEarnings above estimates
Q2-2025: Beat consensus by 100.0% - EPS $0 vs $-4.692 estimate
- mediumEarnings above estimates
Q4-2025: Beat consensus by 100.0% - EPS $0 vs $-1.53 estimate
- mediumEarnings above estimates
Beat consensus by 100.0% - EPS $0 vs $-4.692 estimate
FREE, NO ACCOUNT
Every event on AKTX, as it fires
You are seeing 5 of 8 events recorded on AKTX since 2026-06-09.
The five above landed across 4 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, AKTX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AKTX against its peers
AKTX's return on equity of -61.1% ranks in the 65th percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | AKTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 1.2M | n/a | 7 |
| Operating margin | n/a | -1056.9% | n/a | 6 |
| Net margin | n/a | -345.4% | n/a | 7 |
| Return on equity | -61.1% | -101.4% | 65 | 12 |
Peers (16): CNTX, MCRB, PVCT, QNRX, IMMP, BYSI, COCP, NEUP, KYNB, ATOS, NXTC, JSPR, CELU, CVM, MRKR, NCEL. Left out: PLRZ (no annual filing), SPRC (period gap), IGC (no annual filing), TTIPF (no annual filing), SEOVF (no annual filing), FNCHQ (period gap), EVAX (no annual filing), ZIVO (period gap), MDNAF (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (AKTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow AKTX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to AKTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.